Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT02465060). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 6452 participants (ESTIMATED). Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma. Interventions: DRUG: Adavosertib; DRUG: Afatinib; DRUG: Afatinib Dimaleate; DRUG: Binimetinib; PROCEDURE: Biopsy Procedure; PROCEDURE: Biospecimen Collection; DRUG: Capivasertib; PROCEDURE: Computed Tomography; DRUG: Copanlisib; DRUG: Copanlisib Hydrochloride; DRUG: Crizotinib; OTHER: Cytology Specimen Collection Procedure; DRUG: Dabrafenib; DRUG: Dabrafenib Mesylate; DRUG: Dasatinib; DRUG: Defactinib; DRUG: Defactinib Hydrochloride; PROCEDURE: Echocardiography Test; DRUG: Erdafitinib; DRUG: Fexagratinib; DRUG: Ipatasertib; OTHER: Laboratory Biomarker Analysis; DRUG: Larotrectinib; DRUG: Larotrectinib Sulfate; PROCEDURE: Magnetic Resonance Imaging; PROCEDURE: Multigated Acquisition Scan; BIOLOGICAL: Nivolumab; DRUG: Osimertinib; DRUG: Palbociclib; BIOLOGICAL: Pertuzumab; DRUG: PI3K-beta Inhibitor GSK2636771; PROCEDURE: Radiologic Examination; PROCEDURE: Radionuclide Imaging; BIOLOGICAL: Relatlimab; DRUG: Sapanisertib; DRUG: Sunitinib Malate; DRUG: Taselisib; DRUG: Trametinib; BIOLOGICAL: Trastuzumab; BIOLOGICAL: Trastuzumab Emtansine; DRUG: Ulixertinib; DRUG: Vismodegib. Primary outcome measures: Objective response rate (ORR) , Up to 3 years. Brief summary: This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.